1 |
Ravielione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-6
DOI
ScienceOn
|
2 |
Yew WW, Piddock LJ, Li MB, Lyon D, Chan CY, Cheng AF. In-vitro activity of quinolones and macro lides against mycobacteria. J Antimicrob Chemother 1994;34:343-51
DOI
ScienceOn
|
3 |
Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999;44:393-5
DOI
|
4 |
Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998;2:265-71
|
5 |
Ginsbure AS, Woolwine SC, Hooper N, Benjamin WH Jr, Bishai WR, Dorman SE, et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003;349:1977-8
|
6 |
Ruiz-Serrano MJ, Alcala L, Martinez L, Diaz M, Marin M, Gonzalez-Abad MJ, et al. In vitro acti vities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000;44:2567-8
|
7 |
Frieden TR, Sterline T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-6
DOI
ScienceOn
|
8 |
Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Aeents 2002;20:464-7
|
9 |
Hu Y, Coates AR, Mitchison DA. Sterilizine activities of fluoroquinolones against rifampin-tolerant popul ations of Mycobctcterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-7
|
10 |
Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone and its potential relation to therapeutic efficacy. Clin Drug Invest 1999;17:365-87
|
11 |
Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimzadeh A, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995;345:1148-50
|
12 |
Yamane N, Chilima BZ, Tosaka M, Okazawa Y, Tanno K. Determination of antimycobacterial acti vities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media. Kekkaku 1996;71:453-8
|
13 |
Lee HS, Kang YA, Oh JY, Lee JH, Yoo CG, Lee CT, et al. A case of pulmonary tuberculosis with delayed diagnosis due to the temporary clinical improvement after use of levofloxacin and amikacin under the impression of community acquired pneumonia. Tuberc Respir Dis 2003;55:395-401
|
14 |
Culliton BJ. Drug-resistant TB may bring epidemic. Nature 1992;356:473
|
15 |
Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bon nafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-9
|
16 |
Goble M, Iseman MD, Madsen LA, Waite D, Acker son L, Horsbergh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isomazid and rifampin. N Engl J Med 1993;328:527-32
DOI
ScienceOn
|
17 |
Hoffner SE, Gezelius L, Olsson-Liljegaist B. In-vitro activity of fluorinated quinolones and macrolides against durg-resistant Mycobacterium tuberculosis. J antimicrob Chemother 1997;40:885-8
DOI
ScienceOn
|
18 |
Xa C, Kreiswirth BN, Sreevatsan S, Musser JM, Drlica K. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis 1996;174:1127-30
|